EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Randomized Placebo-Controlled Trial of Mild Hyperbaric Oxygen on Serum Biomarkers in Persistent Post-Concussive Symptoms: Analysis at 13-Week Follow-Up

Emilie E. Vomhof-DeKrey, Olayinka David Ajayi

Trauma Care · 07.05.2026 · 6 (2) · 9

DOI: 10.3390/traumacare6020009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trauma Care, online erschienen am 07.05.2026. Verfasst von Emilie E. Vomhof-DeKrey und 1 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: North Dakota Department of Human Services.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The management of persistent post-concussive symptoms (PPCS) is limited by the absence of objective biomarkers to guide treatment. We examined the early effects of a mild hyperbaric oxygen protocol on serum biomarkers of neuronal injury (neurofilament light chain, NfL), astrogliosis (glial fibrillary acidic protein, GFAP), acute neuronal injury (ubiquitin C-terminal hydrolase L1, UCH-L1), and axonal stability (total tau) in patients with PPCS.

Methods

In this single-center, randomized, placebo-controlled trial, we enrolled adults with PPCS lasting from 3 months to 5 years after mild traumatic brain injury. Participants received 40 sessions of either active treatment (≥99% O2 at 1.5 atmospheres absolute, ATA) or a true chamber placebo (21% O2 with simulated pressure changes). Serum samples were collected at baseline and 13 weeks after treatment. The primary outcome was the difference between groups in serum NfL levels. Analysis was performed on an intention-to-treat basis using a two-way ANOVA with Šídák’s multiple comparison test.

Findings

Of 84 individuals assessed, 20 were randomized (Placebo, n = 9; Intervention, n = 11). Eight from each group received their respective interventions. At 13 weeks, one participant from each group was lost to follow-up, leaving seven per group for analysis. We found no significant differences in serum levels of GFAP, NfL, total tau, or UCH-L1 between the intervention and placebo groups from baseline to 13 weeks.

Conclusions

A 40-session mild hyperbaric oxygen protocol at 1.5 ATA did not significantly change serum biomarkers of neuronal injury, astrogliosis, or acute neuronal damage at 13 weeks post-treatment in individuals with PPCS. This early-phase analysis, at the highest point of participant retention, provides no evidence of a treatment effect on these pathophysiological markers.

Förderung

  • North Dakota Department of Human Services

Zitieren

APA

Vomhof-DeKrey, E. E., & Ajayi, O. D. (2026). A Randomized Placebo-Controlled Trial of Mild Hyperbaric Oxygen on Serum Biomarkers in Persistent Post-Concussive Symptoms: Analysis at 13-Week Follow-Up. Trauma Care, 6(2), 9. https://doi.org/10.3390/traumacare6020009

Vancouver

Vomhof-DeKrey EE, Ajayi OD. A Randomized Placebo-Controlled Trial of Mild Hyperbaric Oxygen on Serum Biomarkers in Persistent Post-Concussive Symptoms: Analysis at 13-Week Follow-Up. Trauma Care. 2026;6(2):9. doi:10.3390/traumacare6020009

BibTeX
@article{VomhofDeKrey2026,
  author = {Vomhof-DeKrey, Emilie E. and Ajayi, Olayinka David},
  title = {A Randomized Placebo-Controlled Trial of Mild Hyperbaric Oxygen on Serum Biomarkers in Persistent Post-Concussive Symptoms: Analysis at 13-Week Follow-Up},
  journal = {Trauma Care},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {9},
  doi = {10.3390/traumacare6020009}
}
Kostenlos starten →